Free Trial

Summit Therapeutics (SMMT) Competitors

Summit Therapeutics logo
$28.67 +1.10 (+3.99%)
Closing price 04:00 PM Eastern
Extended Trading
$28.69 +0.02 (+0.07%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SMMT vs. MRK, GSK, TAK, ARGX, ONC, BNTX, INSM, TEVA, GMAB, and RDY

Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Merck & Co., Inc. (MRK), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector.

Summit Therapeutics vs. Its Competitors

Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$63.92B3.33$17.12B$6.8712.35
Summit Therapeutics$700K30,417.64-$221.32M-$0.34-84.32

Merck & Co., Inc. has a net margin of 27.27% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 43.23% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Merck & Co., Inc.27.27% 43.23% 17.11%
Summit Therapeutics N/A -62.87%-51.61%

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.1% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Merck & Co., Inc. has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500.

In the previous week, Merck & Co., Inc. had 66 more articles in the media than Summit Therapeutics. MarketBeat recorded 74 mentions for Merck & Co., Inc. and 8 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.22 beat Summit Therapeutics' score of 1.14 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merck & Co., Inc.
55 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Merck & Co., Inc. currently has a consensus target price of $108.69, indicating a potential upside of 28.14%. Summit Therapeutics has a consensus target price of $34.67, indicating a potential upside of 20.92%. Given Merck & Co., Inc.'s higher probable upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Summit Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merck & Co., Inc.
1 Sell rating(s)
12 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.43
Summit Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79

Summary

Merck & Co., Inc. beats Summit Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMMT vs. The Competition

MetricSummit TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.29B$2.82B$5.74B$9.51B
Dividend YieldN/A1.78%4.60%3.99%
P/E Ratio-84.329.0428.1120.03
Price / Sales30,417.64744.02461.37103.88
Price / CashN/A166.2336.5559.01
Price / Book54.095.168.655.90
Net Income-$221.32M$30.99M$3.25B$258.66M
7 Day Performance9.43%7.74%4.20%2.23%
1 Month Performance34.79%16.18%10.82%12.76%
1 Year Performance173.31%-1.03%34.70%19.36%

Summit Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMMT
Summit Therapeutics
2.1494 of 5 stars
$28.67
+4.0%
$34.67
+20.9%
+176.3%$21.29B$700K-84.32110Positive News
MRK
Merck & Co., Inc.
4.997 of 5 stars
$79.96
-1.9%
$108.69
+35.9%
-33.1%$200.63B$64.17B11.6375,000Positive News
Upcoming Earnings
Dividend Announcement
GSK
GSK
1.7307 of 5 stars
$36.28
-0.5%
$37.38
+3.0%
-2.8%$74.36B$40.10B18.7268,629Trending News
Upcoming Earnings
Analyst Revision
TAK
Takeda Pharmaceutical
1.6897 of 5 stars
$14.42
-2.2%
N/A+8.0%$45.90B$30.09B65.5747,455Upcoming Earnings
ARGX
argenex
3.6785 of 5 stars
$564.70
-1.4%
$728.06
+28.9%
+27.4%$34.58B$2.25B34.851,599Trending News
Upcoming Earnings
Analyst Revision
ONC
BeOne Medicines
1.2886 of 5 stars
$294.30
+1.4%
$327.56
+11.3%
N/A$32.26B$3.81B-79.1111,000Insider Trade
Gap Up
BNTX
BioNTech
1.409 of 5 stars
$110.03
-0.9%
$136.58
+24.1%
+37.8%$26.49B$2.98B-32.416,772News Coverage
INSM
Insmed
3.9464 of 5 stars
$102.55
-1.6%
$108.47
+5.8%
+39.1%$19.43B$363.71M-17.211,271Positive News
Analyst Forecast
Insider Trade
TEVA
Teva Pharmaceutical Industries
4.166 of 5 stars
$16.07
-1.4%
$24.71
+53.8%
-0.8%$18.44B$16.54B-13.9836,830Positive News
Upcoming Earnings
GMAB
Genmab A/S
4.0631 of 5 stars
$21.89
-0.6%
$37.80
+72.7%
-15.2%$14.04B$3.12B12.442,682Positive News
RDY
Dr. Reddy's Laboratories
2.7247 of 5 stars
$14.49
-1.4%
$16.95
+17.0%
-8.1%$12.09B$3.81B21.9527,811Earnings Report

Related Companies and Tools


This page (NASDAQ:SMMT) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners